Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes-Reference-Cited by-同舟云学术

Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes

Published:2019-09-27 Issue:3 Volume:55 Page:586-594
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Stocker Nicolas^ORCID,Labopin Myriam,Boussen Inès^ORCID,Paccoud Olivier,Bonnin Agnès,Malard Florent,Amiel Corinne,Gozlan Joël,Battipaglia Giorgia,Duléry Rémy,Giannotti Federica,Ruggeri Annalisa,Gaugler Béatrice,Mohty Mohamad,Brissot Eolia

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-019-0699-6.pdf

Reference41 articles.

1. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–16.

2. Patriarca F, Medeot M, Isola M, Battista ML, Sperotto A, Pipan C, et al. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. Transpl Infect Dis. 2013;15:259–67. https://doi.org/10.1111/tid.12061 .

3. Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C, et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transpl. 2008;42:181–6. https://doi.org/10.1038/bmt.2008.150 .

4. Orazi A, Hromas RA, Neiman RS, Greiner TC, Lee CH, Rubin L, et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol. 1997;107:419–29.

5. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation. 1999;68:1517–25.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and prospect in herpesviruses infections after haematopoietic cell transplantation: closer to the finish line?;Clinical Microbiology and Infection;2024-06

2. Epstein–Barr Virus Monitoring after an Allogeneic Hematopoietic Stem Cell Transplant: Review of the Recent Data and Current Practices in Canada;Current Oncology;2024-05-14

3. Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation;Frontiers in Immunology;2024-01-11

4. Epstein-Barr Virus: Acute Infection, Oncogenesis, Prevention and Pitfalls;Global Virology IV: Viral Disease Diagnosis and Treatment Delivery in the 21st Century;2024

5. Rituximab for posttransplant lymphoproliferative disorder – therapeutic, preemptive, or prophylactic?;Bone Marrow Transplantation;2023-11-25